Filter By Price






Report Type
 
The  U.S.  colonic  stents  market  was  valued  at  $6.44  million  in  2018  and  is  projected  to  reach  $9.41  million  by  2026,  registering  a  CAGR  of  4.8%  from  2019  to  2026.  A  colonic  stent  is  used  to  relieve  acute  colonic  obstruction  in  colorectal  cancer  patients.  The  stent  is  compressed  tightly  onto  a  small  delivery  wire  that  allows  the  stent  to  be  positioned  across  the  tight  narrowing  to  relieve  blockage  in  the  colon.  Once  opened,  it  relieves  the  obstruction  by  keeping  the  colon  open  that  can  take  up  to  24  hours  for  the  stent  to  fully  open.  However,  stents  can  be  used  when  there  is  either  a  partial  or  complete  blockage  in  the  bowel  to  reduce  the  pressure  in  the  bowel  and  relieve  the  obstruction.  Further,  stents  are  also  used  when  surgery  is  not  recommended  as  an  alternative  to  keep  the  bowel  working.  It  is  usually  performed  by  specialist  doctors  including  endoscopist  or  by  an  interventional  radiologist  in  the  X-ray  department.

Significant  rise  in  incidences  of  colorectal  cancer  and  benign  strictures  in  the  U.S  are  the  major  factors  driving  the  U.S.  colonic  stents  market.  In  addition,  increase  in  demand  for  minimally  invasive  procedures  and  technological  advancements  regarding  the  development  of  more  compatible  metallic  stents  further  propels  the  market  growth  of  colonic  stents  in  the  near  future.  However,  complications  and  high  costs  associated  with  colonic  stents  is  anticipated  to  hamper  the  growth  of  the  colonic  stents  market  in  the  U.S.  Moreover,  colonic  stenting  improves  the  primary  anastomosis  rate  with  a  low  stoma  creation  in  comparison  with  emergency  surgery.  Improved  colonic  stent  such  as  self-expandable  metallic  stents  (SEMS)  is  used  for  the  bridge  to  surgery  and  it  also  able  to  cure  patients  with  the  palliative  intent  with  advanced  neoplastic  disease,  to  avoid  stoma  and  health  care  costs  related  to  stoma.  This  provides  a  lucrative  opportunity  for  the  growth  of  the  U.S.  colonic  stents  market.

The  report  covers  the  U.S.  colonic  stents  market  forecast  and  analysis  based  on  three  categories  that  include  product  type,  indication,  and  end  user.  Based  on  product  type,  the  market  is  categorized  into  nitinol  self-expandable  metal  stents,  and  elgiloy  self-expandable  metal  stents.  On  the  basis  of  indication,  it  is  categorized  into  colorectal  cancer,  colonic  benign  strictures  and  others.  By  end  user,  the  market  is  bifurcated  into  hospitals  and  specialty  clinics.

KEY  BENEFITS  FOR  STAKEHOLDERS
• This  report  entails  a  detailed  quantitative  analysis  along  with  the  current  U.S.  colonic  stents  market  trends  from  2019  to  2026  to  identify  the  prevailing  opportunities  along  with  the  strategic  assessment.

• The  market  size  and  estimations  are  based  on  a  comprehensive  analysis  of  key  developments  in  the  industry.  
• A  qualitative  analysis  based  on  innovative  products  facilitates  strategic  business  planning.

• The  development  strategies  adopted  by  the  key  market  players  are  enlisted  to  understand  the  competitive  scenario  of  the  market
Key  Market  Segments
Key  Market  Segments
By  Product  Type
Self-Expandable  Metal  Stents
o Nitinol  Stent
o Elgiloy
By  Indication
• Colorectal  Cancer/Bridge  to  Surgery
• Benign  Colonic  Strictures
• Other  Indications

By  End  User
• Hospitals
• Specialty  Clinics

The  key  players  profiled  in  this  report  are  as  follows:
• Boston  Scientific  Corporation
• Cook  Medical  Inc
• Cook  Medical  Inc
• Taewoong
• MI-TECH
• Olympus  Corporation
 
The  global  urinary  self-catheters  market  was  valued  at  $1,722  million  in  2018,  and  is  projected  to  reach  $2,387  million  by  2026,  registering  a  CAGR  of  4.1%  from  2019  to  2026.  

A  urinary  catheter  is  a  hollow,  partially  flexible  tube,  which  is  used  to  drain  the  urine  when  an  individual  is  unable  to  do  it  naturally.  These  catheters  consist  of  a  drainage  bag  that  assists  to  collect  a  urine.  They  are  composed  of  silicone,  PVC,  or  vinyl  or  red  rubber  latex.  
The  urinary  self-catheter  market  is  expected  to  exhibit  significant  market  growth  during  the  forecast  period,  owing  to  increase  in  prevalence  of  benign  prostate  hyperplasia  (BPH),  urinary  incontinence,  and  spinal  cord  injuries;  rise  in  number  of  surgeries,  and  increase  in  geriatric  population.  Upsurge  in  demand  for  hydrophilic  intermittent  catheters  and  favorable  reimbursement  policies  for  usage  of  urinary  catheters  further  supplement  the  market  growth.  
Innovations  in  catheters,  novel  product  launches,  and  rise  in  demand  for  intermittent  catheters  in  emerging  economies  provide  lucrative  opportunities  for  the  market  expansion.  However,  the  availability  of  substitutes  of  catheters  and  lack  of  awareness  toward  utilization  of  self-catheters  hamper  the  market  growth.  
The  global  urinary  self-catheters  market  is  segmented  based  on  product,  type,  application,  and  region.  Depending  on  product,  the  market  is  bifurcated  into  intermittent  catheters  and  external  catheters.  Intermittent  catheters  are  further  classified  into  uncoated  intermittent  catheters  and  coated  intermittent  catheters.  Coated  intermittent  catheters  are  subsegmented  into  antimicrobial,  hydrophilic,  and  others.  According  to  type,  the  market  is  categorized  into  male  type  catheter  and  female  type  catheter.  By  application,  it  is  divided  into  benign  prostate  hyperplasia  (BPH),  urinary  incontinence,  spinal  cord  injuries,  and  others.  Region  wise,  it  is  studied  across  North  America  (U.S.,  Canada,  and  Mexico),  Europe  (Germany,  France,  the  UK,  Italy,  Spain,  and  rest  of  Europe),  Asia-Pacific  (China,  Japan,  Australia,  India,  South  Korea,  Taiwan,  and  rest  of  Asia-Pacific),  and  LAMEA  (Brazil,  South  Africa,  Saudi  Arabia,  Turkey,  and  rest  of  LAMEA).  

 
KEY  BENEFITS  FOR  STAKEHOLDERS
• The  study  provides  an  in-depth  analysis  of  the  market  along  with  the  current  trends  and  future  estimations  to  elucidate  the  imminent  investment  pockets.

• It  offers  a  quantitative  analysis  from  2018  to  2026,  which  is  expected  to  enable  the  stakeholders  to  capitalize  on  the  prevailing  market  opportunities.  
• A  comprehensive  analysis  of  all  the  geographical  regions  is  provided  to  determine  the  existing  opportunities.

• The  profiles  and  growth  strategies  of  the  key  players  are  thoroughly  analyzed  to  understand  the  competitive  outlook  of  the  global  market.


KEY  MARKET  SEGMENTS
By  Product  
• Intermittent  Catheter
o Uncoated  Intermittent  Catheters
o Coated  Intermittent  Catheters
? Antimicrobial  Intermittent  catheters
? Hydrophilic  Intermittent  catheters
? Others
• External  Catheter

Type
• Male  Type  Catheter
• Female  Type  Catheter

Application
• Benign  Prostate  Hyperplasia  (BPH)
• Urinary  Incontinence
• Spinal  Cord  Injuries
• Others


By  Region
• North  America
o U.S.

o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest  of  Europe
• Asia-Pacific
o Japan
o China  
o Australia
o India
o South  Korea
o Taiwan
o Rest  of  Asia-Pacific
• LAMEA
o Brazil
o Saudi  Arabia
o South  Africa
o Turkey  
o Rest  of  LAMEA
LIST  OF  KEY  PLAYERS  PROFILED  IN  THE  REPORT
• Asid  Bonz  GmbH
• B  Braun  Melsungen  AG
• Becton  Dickson  and  Company  (C.R.  Bard)
• Boston  Scientific  Corporation
• Coloplast  A/S
• ConvaTec
• Hollister,  Inc.

• Medical  Technologies  of  Georgia,  Inc.

• Medtronic  plc.

• Teleflex  Incorporated      

LIST  OF  OTHER  PLAYERS  IN  THE  VALUE  CHAIN  (These  players  are  not  profiled  in  the  report.  The  same  will  be  included  on  request.)
• Cure  Medical
• Pennine  Healthcare
Natural  killer  (NK)  cell  is  a  component  of  innate  immunity  system  that  targets  cancer  cells,  and  can  be  used  as  a  therapeutic  agent.  NK  cells  target  the  cells  losing  MHC-I  in  cancer,  a  phenotype  that  is  similar  to  certain  cells  in  immune-privileged  sites  whose  milieus  are  separated  from  peripheral  blood.

The  global  natural  killer  cell  therapeutics  market  was  valued  at  $1,402  million  in  2018,  and  is  projected  to  reach  $5,096  million  by  2026,  registering  a  CAGR  of  17.4%  from  2019  to  2026.  
The  growth  of  the  global  natural  killer  cell  therapeutics  market  is  driven  by  rise  in  use  of  NK  cells  to  treat  cancer,  infections,  and  liver  diseases.  Moreover,  NK  cells  play  vital  role  in  tumor  immune-surveillance,  which  has  significantly  boosted  their  adoption  across  the  globe.  In  addition,  rise  in  awareness  among  the  population  regarding  various  immunotherapies  and  increase  in  R&D  for  the  development  of  bi-specific  antibody  for  engaging  NK  cells  to  eliminate  tumor  cells  propel  the  global  natural  killer  cell  therapeutics  market  growth.  However,  lack  of  specificity  and  poor  in-vivo  survival  of  the  cells  limit  the  growth  of  the  market.  Furthermore,  higher  costs  associated  with  the  therapies  and  adverse  side  effects  are  expected  to  hamper  the  market  growth  in  the  coming  years.  Conversely,  significant  surge  in  R&D  activities  toward  development  of  immunotherapy  in  developing  economies  is  anticipated  to  offer  lucrative  opportunities  for  the  market.

The  global  natural  killer  cell  therapeutics  market  is  segmented  based  on  therapeutics,  application,  end  user,  and  region.  Depending  on  therapeutics,  the  natural  killer  cells  therapeutics  market  is  classified  into  NK  cell  therapies  and  NK  cell  directed  antibodies.  By  application,  it  is  categorized  into  cancer,  gastrointestinal  diseases,  immunoproliferative  disorders,  and  others.  On  the  basis  of  end  user,  it  is  segregated  into  hospitals,  research  centers  &  institutes,  and  others.  Region  wise,  it  is  analyzed  across  North  America,  Asia-Pacific,  Europe,  and  LAMEA.

KEY  BENEFITS  FOR  STAKEHOLDERS
• This  report  entails  a  detailed  quantitative  analysis  along  with  the  current  market  trends  from  2019  to  2026  to  identify  the  prevailing  opportunities  along  with  the  strategic  assessment.

• The  global  natural  killer  cell  therapeutics  market  size  and  estimations  are  based  on  a  comprehensive  analysis  of  key  developments.  
• A  qualitative  analysis  based  on  innovative  products  facilitates  strategic  business  planning.

• The  development  strategies  adopted  by  the  key  market  players  are  enlisted  to  understand  the  competitive  scenario  of  the  market
Key  Market  Segments
• By  Therapeutics
o NK  Cell  Therapies
o NK  Cell  Directed  Antibodies

• By  Application
o Cancer  
o Gastrointestinal  Diseases
o Immunoproliferative  Disorders
o Others

• By  End  User
o Research  Centers  &  Institutes  
o Hospitals
o Others

• By  Region
o North  America
? U.S.

? Canada
? Mexico
o Europe
? Germany  
? France  
? UK  
? Italy
? Spain
? Rest  of  Europe
o Asia-Pacific
? Japan  
?  China  
?  India  
?  Australia  
? Rest  of  Asia-Pacific
o LAMEA
? Brazil  
?  Saudi  Arabia  
?  South  Africa
?  Rest  of  LAMEA

The  key  players  profiled  in  this  report  are  as  follows:
• Affimed  N.V.

• Celgene  Corporation
• Fate  Therapeutics
• Fortress  Biotech
• Glycostem  Therapeutics  BV
• Innate  Pharma  S.A.

• Nantkwest  Inc.

• Nkarta  Therapeutics,  Inc.

• NKT  Therapeutics  Inc.

• Ziopharm  Oncology  Inc.  
The  global  multiplex  assays  market  accounted  for  $73.2  million  in  2018,  and  is  expected  to  reach  $123.1  million  by  2026,  growing  at  a  CAGR  of  6.6%  from  2019  to  2026.

Multiplex  immunoassays  conjugates  assays  for  several  target  analytes  in  a  single  reaction  volume,  minimizing  workflow  and  sample  volume  difficulties.  In  addition,  this  assay  provides  a  gain  in  assay  dynamic  range,  and  is  used  to  amplify  multiple  targets  in  a  polymerase  chain  reaction  (PCR)  and  collect  more  information  from  minute  quantities  of  proteins  or  other  analytes  in  lesser  time  as  compared  to  conventional  methods  such  as  singleplex  ELISA.  Multiplex  assays  finds  its  application  in  pathogen  identification,  mutation  analysis,  RNA  detection,  gene  detection  analysis,  linkage  analysis,  forensic  studies,  and  others.  

Multiplex  assays  hold  enormous  potential  in  the  R&D  of  drugs  for  the  treatment  of  diseases,  such  as  cancer  and  cardiovascular  diseases  that  drives  the  market  growth  for  theses  assays.  For  instance,  bead-based  Luminex  xMAP  multiplex  assay  provides  a  platform  for  cancer  biomarker  assays,  which  are  compatible  with  plasma,  serum,  cultured  cells,  and  other  biological  samples.  In  addition,  surge  in  adoption  of  multiplex  assays  to  reduce  operation  costs  and  rise  in  adoption  of  personalized  medicines  are  anticipated  to  boost  the  market  growth.  However,  high  capital  investment  and  dearth  of  skilled  labors  are  the  major  factors  that  hinder  the  market  growth.  On  the  contrary,  the  emerging  economies  of  Asia-Pacific  and  LAMEA  regions  offer  lucrative  growth  opportunities  for  the  expansion  of  multiplex  assays  market,  due  to  improvement  in  healthcare  infrastructure  in  these  regions  and  increase  in  demand  for  better  healthcare  services  from  majority  of  the  patient  population.


The  global  multiplex  assays  market  in  this  report  is  studied  based  on  type,  product,  technology,  application,  end  user,  and  region.  On  the  basis  of  type,  the  market  is  divided  into  nucleic  acid-based,  protein-based  multiplex  assays,  and  others.  By  product,  it  is  classified  into  multiplex  assay  reagents  &  consumables,  multiplex  assay  instruments  &  accessories,  and  multiplex  assay  software  &  services.  Depending  on  technology,  it  is  fragmented  into  nucleic  acid-based,  protein-based  multiplex  assays,  and  others.  As  per  application,  it  is  segregated  into  companion  diagnostics,  research  &  development,  clinical  diagnostics,  and  others.  According  to  end  user,  it  is  classified  into  hospitals,  clinical  laboratories,  research  institutes,  and  pharmaceuticals  &  biotechnological  companies.  Region  wise,  it  is  analyzed  across  North  America,  Europe,  Asia-Pacific,  and  LAMEA.



KEY  BENEFITS  FOR  STAKEHOLDERS

? The  study  provides  an  in-depth  analysis  of  the  global  multiplex  assay  market  along  with  the  current  trends  and  future  estimations  to  elucidate  the  imminent  investment  pockets.

? A  comprehensive  analysis  of  the  factors  that  drive  and  restrict  the  market  growth  is  provided.

? A  comprehensive  quantitative  analysis  of  the  industry  is  provided  from  2018  to  2025  to  assist  stakeholders  to  capitalize  on  the  prevailing  market  opportunities.

? An  extensive  analysis  of  the  key  segments  of  the  industry  helps  to  understand  the  global  trends  in  the  multiplex  assay  market.

? Key  players  and  their  strategies  are  provided  to  understand  the  competitive  outlook  of  the  industry.


? KEY  MARKET  SEGMENTS
By  Type
• Nucleic  Acid-based  Multiplex  Assays  
• Protein-based  Multiplex  Assays  
• Others  
By  Product
• Multiplex  Assay  Reagents  &  Consumables
• Multiplex  Assay  Instruments  &  Accessories
• Multiplex  Assay  Software  &  Services
By  Technology
• Multiplex  PCR
• Multiplex  Protein  Microarray
• Others  
By  Application  
• Companion  Diagnostics
• Research  &  Development
• Clinical  Diagnostics
End  User
• Hospitals
• Clinical  Laboratories
• Research  Institutes
• Pharmaceuticals  &  Biotechnological  Companies

By  Region
o North  America
• U.S.

• Canada
• Mexico
o Europe
• UK
• France
• Germany
• Italy
• Spain
• Rest  of  Europe
o Asia-Pacific
• Japan
• China
• India
• South  Korea
• Australia
• Rest  of  Asia-Pacific
o LAMEA  
• Saudi  Arabia
• South  Africa
• Brazil
• Rest  of  LAMEA

KEY  MARKET  PLAYERS  
• Luminex  Corporation
• Thermo  Fisher  Scientific  Inc.

• Illumina  Inc.

• Bio-Rad  Laboratories  Inc.

• QIAGEN  N.V.

• Becton,  Dickinson  and  Company
• Abcam  PLC
• Seegene  Inc.

• Randox  Laboratories  Ltd.

The  other  players  in  the  value  chain  include  (profiles  not  included  in  the  report)

• Merck  KGaA
• Agilent  Technologies
• Quanterix
• Olink
• Sysmex  Corporation
• Siemens  Healthcare  GmbH
• F.  Hoffmann-La  Roche  Ltd
• Johnson  &  Johnson
 The  Vietnam  menstrual  cups  market  size  was  $1.521  million  in  2018  and  is  projected  to  reach  $2.264  million  by  2026,  registering  a  CAGR  of  5.2%  from  2019  to  2026.


A  menstrual  cup  is  a  feminine  hygiene  product  that  is  used  during  menstruation.  It  is  inserted  into  the  vagina  and  one  can  keep  it  inside  for  a  maximum  duration  of  12  hours.  Its  purpose  is  to  prevent  menstrual  blood  from  leaking  onto  the  clothes.  It  is  made  up  of  either  latex,  silicone,  or  thermoplastic  elastomer.  Silicon  and  thermoplastic  elastomer  are  hypoallergic,  which  means  that  the  wearer  can  be  safe  from  unwanted  irritation  and  allergies.  The  menstrual  cups  are  available  in  smaller  and  larger  size,  where  smaller  size  is  recommended  for  women  under  30  (who  have  not  given  birth  vaginally)  and  the  larger  size  is  recommended  for  women  who  are  over  30  (have  given  birth  vaginally  or  experience  a  heavy  flow).


The  major  factors  that  drive  the  growth  of  the  Vietnam  menstrual  cups  market  include  increase  in  awareness  among  the  population  about  the  available  options  during  menstruation.  Huge  number  of  awareness  campaigns  conducted  by  women  communities,  educational  institutes,  and  non-profit  organizations  also  help  in  the  growth  of  the  market.  In  addition,  rise  in  women  populace  coupled  with  high  costs  of  sanitary  pads  and  tampons  further  fuels  the  market  growth.  However,  additional  substitutes  coupled  with  high  cost  of  menstrual  cups  as  well  as  cultural  resistance  &  limited  level  of  acceptance  of  these  sanitary  protections  are  expected  to  hamper  the  market  growth.  On  the  contrary,  rise  in  awareness  about  eco-friendly  and  safety  sanitary  protections  is  anticipated  to  create  lucrative  opportunities  for  the  menstrual  cup  manufacturers  in  Vietnam  in  the  near  future.


The  Vietnam  menstrual  cups  market  is  segmented  based  on  product  type,  material,  and  distribution  channel.  Based  on  product  type,  the  market  is  bifurcated  into  disposable  menstrual  cups  and  reusable  menstrual  cups.  Based  on  material,  the  market  is  divided  into  medical  grade  silicones,  natural  latex  rubber,  and  thermoplastic  elastomer.  Based  on  distribution  channel,  the  market  is  categorized  into  online  stores  and  pharmacies/retail  stores.


KEY  BENEFITS  FOR  STAKEHOLDERS

?  This  report  provides  a  detailed  quantitative  analysis  of  the  current  market  trends  and  future  estimations  from  2019  to  2026,  which  assists  to  identify  the  prevailing  market  opportunities.  
?  A  comprehensive  analysis  of  the  factors  that  drive  and  restrain  the  growth  of  the  Vietnam  menstrual  cups  market  is  provided.

?  An  extensive  analysis  of  various  regions  provides  insights  that  allow  companies  to  strategically  plan  their  business  moves.


KEY  MARKET  SEGMENTS
•  By  Product  Type
o  Reusable  Menstrual  Cups
o  Disposable  Menstrual  Cups
•  By  Material
o  Medical  grade  silicones
o  Natural  Latex  Rubber
o  Thermoplastic  elastomer
•  By  Distribution  Channel
o  Online  Stores
o  Pharmacies/Retail  Stores
KEY  MARKET  PLAYERS  
•  Anigan
•  Diva  International  Inc.

•  Fleurcup
•  Jaguara,  s.r.o.

•  Lingroup  Co.,  Ltd.  (Lintimate)
•  Lune  Group  Oy  Ltd.

•  Lena  Cup
•  Mooncup  Ltd.

•  Me  Luna  GmbH
•  OVA  Vietnam  Company  Limited
•  Sterne  (Si-Line)
•  YUUKI  Company  s.r.o.
 
 The  global  menstrual  cup  market  accounted  for  around  $1,213  million  in  2018  and  is  expected  to  reach  $1,894  million  by  2026,  registering  a  CAGR  of  5.7%  from  2019  to  2026.  A  menstrual  cup  is  a  feminine  hygiene  product  that  are  used  during  menstruation.  It  is  inserted  into  the  vagina  and  one  can  keep  it  inside  for  maximum  12  hours.  Its  purpose  is  to  prevent  menstrual  blood  from  leaking  onto  the  clothes.  It  is  made  up  of  either  latex,  silicone,  or  thermoplastic  elastomer.  Silicon  and  thermoplastic  elastomer  are  hypoallergic  which  means  that  the  wearer  can  be  safe  from  unwanted  irritation  and  allergies.  The  menstrual  cups  are  available  in  a  smaller  and  a  larger  size,  where  smaller  size  is  recommended  for  women  under  30  (who  have  not  given  birth  vaginally)  and  the  larger  size  is  recommended  for  women  who  are  over  30  (have  given  birth  vaginally  or  have  a  heavy  flow).


The  menstrual  cup  market  is  expected  to  witness  significant  growth  during  the  forecast  period  due  to  the  factors  such  as  rise  in  demand  &  increase  in  awareness  for  advanced  feminine  hygiene  products.  Moreover,  menstrual  cups  also  help  prevent  odor,  hold  more  blood  than  pads  or  tampon,  and  are  more  hygienic  as  compared  to  the  pads  and  tampons.  These  menstrual  cups  are  made  up  of  the  medically  graded  researched  material  making  them  safe  to  be  inserted  into  the  body.  However,  the  menstrual  cups  can  be  messier  to  use,  and  hard  to  insert  &  remove.  Sometimes  menstrual  cups  can  also  cause  allergic  reaction,  which  hinders  the  growth  of  the  menstrual  cup  market.  However,  increase  in  focus  on  product  innovation  for  feminine  hygiene  products  and  emphasizing  on  production  of  menstrual  cup  made  from  organic  and  biodegradable  materials  can  help  open  new  avenues  for  the  growth  of  menstrual  cup  market.


The  global  menstrual  cup  market  is  segmented  based  on  product  type,  material  type,  and  end  user.  Based  on  product  type,  the  market  is  bifurcated  into  disposable  and  reusable  menstrual  cup.  Based  on  material  type,  the  market  is  classified  into  medical  grade  silicone,  natural  gum  rubber  (latex)  and  thermoplastic  elastomer  (TPE).  Based  on  distribution  channel,  the  market  is  categorized  into  online  stores  and  pharmacies  &  retail  stores.  Based  on  region,  the  market  is  analyzed  across  North  America,  Europe,  Asia-Pacific,  and  LAMEA.


Major  key  players  operating  in  menstrual  cup  market  are  Diva  International  Inc.,  Lunette,  The  Keeper,    Inc.,  Femcap,  Mooncup  Ltd.,  Fleurcup,  MeLuna  USA,  Lena  Cup,  Lingroup  Co.,  Ltd.,  Jaguara,  s.r.o,  Anigan,  Vcup,  and  Yuuki  Company  s.r.o.


KEY  BENEFITS  FOR  STAKEHOLDERS

?  This  report  highlights  the  market  dynamics  to  understand  the  global  Menstrual  Cup  market  and  capitalize  on  the  prevailing  opportunities.

?  Quantitative  analysis  of  the  current  market  and  forecasts  would  assist  stakeholders  to  design  business  strategies  accordingly.  
?  Porter's  five  forces  analysis  examines  the  competitive  market  structure  and  provides  a  deeper  understanding  of  the  influencing  factors  for  entry  and  expansion.

?  Pin-point  analysis  of  geographical  segments  offers  identification  of  most  profitable  segments  to  capitalize  on.


KEY  MARKET  SEGMENTS
•  By  Type  
o  Arthrospira  Platensis
o  Arthrospira  Maxima
•  By  Application  
o  Nutraceuticals
o  Food  and  Beverages
o  Cosmetics
o  Agriculture
o  Feed
o  Others
•  By  Drug  Formulation
o  Powder
o  Tablet  &  Capsule
o  Liquid
o  Granule  &  Gelling  Agent
•  By  Region
o  North  America
•  U.S.

•  Canada
•  Mexico
o  Europe
•  Germany
•  France
•  Spain
•  Italy
•  UK
•  Rest  of  Europe
o  Asia-Pacific
•  Australia
•  Japan
•  India
•  China
•  Rest  of  Asia-Pacific
o  LAMEA
•  Brazil
•  Saudi  Arabia
•  South  Africa
•  Rest  of  LAMEA
KEY  MARKET  PLAYERS  
•  Ligand  Pharmaceuticals
•  Addrenex  Pharmaceuticals
•  Shire  Plc
•  Teva  Pharmaceutical  Industries  Ltd.

•  Arena  Pharmaceuticals
•  Jazz  Pharmaceuticals  Plc
•  Bioprojet
•  Graymark  Healthcare,  Inc.
 
 The  global  elderly  &  disabled  assistive  devices  market  size  was  $23,009  million  in  2018  and  is  anticipated  to  reach  $35,599  million  by  2026,  registering  a  CAGR  of  5.5%  from  2019  to  2026.  Assistive  devices,  as  the  term  signifies  are  the  medical  devices  that  assist  elderly  as  well  as  disabled  people  to  form  their  various  basic  tasks  such  as  walking,  hearing  problems,  vision  problems,  and  others.  The  mobility  aids  devices  include  wheelchairs,  scooters,  and  others  that  alleviate  disabled  individuals  with  their  mobility.  Moreover,  there  are  various  kinds  of  hearing  aids  that  help  individuals  with  hearing  difficulties  such  as  Behind-the-ear  Aids  (BTE),  Receiver-in-the-Ear  Aids  (RITE),  In-the-Ear  Aids  (ITE),  Bone  Anchored  Hearing  Aids  (BAHA),  canal  hearing  aids  and  cochlear  implants.

The  global  elderly  and  disabled  assistive  devices  market  is  primarily  driven  by  significant  rise  in  mobility  impairment  disorders,  lifestyle  changes,  and  availability  of  a  variety  of  disabled  &  elderly  assistive  products.  In  addition,  considerable  increase  in  demand  for  assistive  devices  due  to  rise  in  trend  of  an  independent  lifestyle  further  fuels  the  market  growth.  Furthermore,  growth  in  the  number  of  assistive  devices  manufacturers  investing  in  the  R&D  activities  of  these  technologies  is  estimated  to  boost  the  market  growth.  However,  high  cost  of  few  sophisticated  products,  low  level  of  acceptance  for  few  products,  and  low  reimbursement  from  medical  insurers  restrain  the  growth  of  the  market.  On  the  contrary,  an  increase  in  proactiveness  of  people  and  rise  in  health  consciousness  among  people  are  anticipated  to  provide  lucrative  growth  opportunities  for  the  market  growth.

The  global  elderly  &  disabled  assistive  devices  market  is  segmented  based  on  type  and  region.  Based  on  type,  it  is  divided  into  living  aids,  mobility  aids  devices,  medical  furniture,  and  bathroom  safety  equipment.  Based  on  region,  it  is  analyzed  across  North  America,  Europe,  Asia-Pacific,  and  LAMEA.

KEY  BENEFITS  FOR  STAKEHOLDERS
• This  report  provides  an  extensive  analysis  of  the  emerging  trends  and  dynamics  in  the  global  elderly  &  disabled  assistive  devices  market.

• This  study  provides  the  landscape  of  the  global  market  to  predict  the  competitive  environment  across  geographies.

• This  report  entails  the  detailed  quantitative  analyses  of  the  current  trends  and  future  estimations  to  identify  the  prevailing  opportunities.

• Comprehensive  analyses  of  factors  that  drive  and  restrict  the  market  growth  is  provided  in  the  report.

• Region-  and  country-wise  analysis  is  conducted  to  understand  the  market  trends  and  dynamics.

KEY  MARKET  SEGMENTS
By  Type
• Living  Aids  Devices  
o Hearing  Aids
? Behind-the-ear  Aids  (BTE)  
? Receiver-in-the-Ear  Aids  (RITE)
? In-the-Ear  Aids  (ITE)
? Bone  Anchored  Hearing  Aids  (BAHA)
? Canal  Hearing  Aids
? Cochlear  Implants
o Reading  and  Vision  Aids
? Braille  Translators
? Video  Magnifiers
? Reading  Machines
? Others  
• Mobility  Aids  Devices
o Wheelchairs
? Manual  Wheelchairs
? Powered  Wheelchairs
o Mobility  Scooters
? Walkers  &  Rollators
? Canes  &  Walking  Sticks
? Crutches
? Transfer  Lifts  or  Patient  Mechanical  Lift  Handling
? Door  Openers
? Others
• Medical  Furniture
o Medical  Beds
o Door  Openers
o Medical  Furniture  Accessories
o Riser  Reclining  Chairs
o Others
• Bathroom  Safety  Equipment
o Shower  Chairs
o Commodes
o Ostomy  Products
o Bars,  Grips,  &  Rails
• By  Region
o North  America
? U.S.

? Canada
? Mexico
o Europe
? Germany  
? France  
? UK  
? Italy
? Spain
? Rest  of  Europe
o Asia-Pacific
? Japan  
?  China  
?  India  
?  Australia  
? Rest  of  Asia-Pacific
o LAMEA
? Brazil  
?  Saudi  Arabia  
?  South  Africa
?  Rest  of  LAMEA


The  key  players  profiled  in  this  report  are  as  follows:
• AI  Squared
• Drive  Medical.

• GN  Resound  Group.

• Invacare
• William  Demant  Holding  A/S
• Nordic  Capital  (Sunrise  Medical  LLC)
• Pride  Mobility  Products  Corporation
• Siemens  Ltd
• Sonova  Holding  AG
• Starkey  hearing  technologies
The  other  players  operating  in  the  elderly  &  disabled  assistive  devices  market  include  (not  profiled  in  the  report)
• Bausch  &  Lomb,  Inc.,
• Inclusive  Technology  Ltd.

• Liberator  Ltd.

• Tobii  Dynavox
• JABBLA  B.V.B.A
• Blue  Chip  Medical  Type,  Inc.

• Permobil  AB
• Medline  Industries,  Inc.
 The  global  companion  diagnostics  market  generated  $1,678  million  in  2018,  and  is  projected  to  reach  $6,452  million  by  2026,  growing  at  a  CAGR  of  18.3%  from  2019  to  2026.


Companion  diagnostic  is  a  medical  device,  often  an  in-vitro  device  that  provides  information  essential  for  the  safe  and  effective  use  of  a  corresponding  drug  or  biological  product.  These  tests  help  a  health  care  professional  to  determine  patients  who  can  benefit  from  a  particular  therapeutic  product,  identify  patients  at  increased  risk  of  severe  side  effects  as  a  result  of  the  treatment  with  a  particular  therapeutic  product  as  well  as  achieve  improved  safety  or  effectiveness.  

The  companion  diagnostics  market  is  expected  to  experience  significant  growth  during  the  forecast  period  owing  to  growth  in  demand  for  advanced  therapies,  rise  in  R&D  activities  to  develop  low  cost  &  highly  efficient  drugs,  increase  in  awareness  in  personalized  medicines  and  surge  in  demand  for  cost  effective  diagnosis  are  some  factors  that  majorly  drive  the  market  growth.    

The  global  companion  diagnostics  market  is  segmented  based  on  technology,  indication,  and  region.  Based  on  technology,  the  market  is  categorized  as  immunohistochemistry,  polymerase  chain  reaction  (PCR),  next  Generation  Sequencing  (NGS),  in  situ  hybridization,  and  others.  On  the  basis  of  indication,  it  is  segmented  into  oncology,  neurology,  and  others.  Oncology  is  further  classified  into  lung  cancer,  colorectal  cancer,  breast  cancer,  blood  cancer,  and  others.  Based  on  region,  the  market  is  studied  across  North  America  (U.S.,  Canada,  and  Mexico),  Europe  (Germany,  France,  the  UK,  and  rest  of  Europe),  Asia-Pacific  (China,  Japan,  Australia,  and  rest  of  Asia-Pacific),  and  LAMEA  (Brazil,  South  Africa  and  rest  of  LAMEA).    

 
KEY  BENEFITS  FOR  STAKEHOLDERS
•  The  study  provides  an  in-depth  analysis  of  the  market  along  with  the  current  trends  and  future  estimations  to  elucidate  the  imminent  investment  pockets.

•  It  offers  a  quantitative  analysis  from  2018  to  2026,  which  is  expected  to  enable  the  stakeholders  to  capitalize  on  the  prevailing  market  opportunities.  
•  A  comprehensive  analysis  of  all  the  regions  is  provided  to  determine  the  existing  opportunities.

•  The  profiles  and  growth  strategies  of  the  key  players  are  thoroughly  analyzed  to  understand  the  competitive  outlook  of  the  global  market.


KEY  MARKET  SEGMENTS

By  Technology  Type  
•  Immunohistochemistry
•  Polymerase  chain  reaction  (PCR)
•  Next  Generation  Sequencing  (NGS)
•  In  situ  hybridization
•  Others

Indication  
•  Oncology
o  Lung  cancer
o  Colorectal  cancer
o  Breast  cancer
o  Blood  cancer
o  Others
•  Neurology
•  Others

By  Region
•  North  America
o  U.S.

o  Canada
o  Mexico
•  Europe
o  Germany
o  France
o  UK
o  Rest  of  Europe
•  Asia-Pacific
o  Japan
o  China  
o  Australia
o  Rest  of  Asia-Pacific
•  LAMEA
o  Brazil
o  South  Africa
o  Rest  of  LAMEA
LIST  OF  KEY  PLAYERS  PROFILED  IN  THE  REPORT
•  Abbott  Laboratories  Molecular,  Inc.

•  Agilent  (Dako  Denmark  A/S)
•  ARUP  Laboratories,  Inc.

•  BioMerieux  SA
•  Danaher  Corporation  (Leica  Microsystems)
•  Foundation  Medicine,  Inc.

•  Myriad  Genetics,  Inc.

•  Qiagen  N.V.

•  Roche  (Ventana  Medical  Systems,  Inc.)
•  Thermo  Fisher  Scientific  (Life  Technologies  Corporation)      

LIST  OF  OTHER  PLAYERS  IN  THE  VALUE  CHAIN  (These  players  are  not  profiled  in  the  report.  The  same  will  be  included  on  request.)
•  Resonance  Health  Ltd
 The  use  of  targeted,  biologic  (immunotherapy)  &  other  forms  of  therapies  administered  to  treat  cancer  through  oncology  drugs  is  known  as  cancer  therapeutics.  The  global  cancer  therapeutics  market  size  was  valued  at  $98,900  million  in  2018  and  is  estimated  to  reach  at  $180,193  million  by  2026,  registering  a  CAGR  of  7.7%  from  2019  to  2026.

Upsurge  in  collaboration  between  pharmaceutical  companies,  rise  in  cancer  awareness  &  availability  of  oncology  drugs,  increase  in  cancer  funding  &  research,  and  growth  in  geriatric  population  are  the  key  factors  that  augment  the  growth  of  the  cancer  therapeutics  market.  Furthermore,  rise  in  prevalence  of  cancer  cases  is  expected  to  boost  the  market  growth.

However,  adverse  effects  associated  with  cancer  therapeutics  market  and  high  costs  associated  with  oncology  drug  development  are  some  of  the  factors  that  impede  the  market  growth.  Conversely,  the  high  potential  of  emerging  economies  and  increase  in  demand  for  personalized  medicine  is  expected  to  provide  new  opportunities  for  the  market  players  in  future.

The  cancer  therapeutics  market  is  segmented  based  on  application,  top  selling  drugs,  and  region.  Based  on  application,  the  market  is  divided  into  blood  cancer,  lung  cancer,  colorectal  cancer,  prostate  cancer,  breast  cancer,  cervical  cancer,  head  &  neck  cancer,  glioblastoma,  malignant  meningioma,  mesothelioma,  melanoma,  and  others.  By  top  selling  drugs,  it  is  categorized  into  Revlimid,  Avastin,  Herceptin,  Rituxan,  Opdivo,  Gleevec,  Velcade,  Imbruvica,  Ibrance,  Zytiga,  Alimta,  Xtandi,  Tarceva,  Perjeta,  Temodar  and  others.  Region  wise,  it  is  analyzed  across  North  America,  Europe,  Asia-Pacific,  and  LAMEA.


KEY  BENEFITS  FOR  STAKEHOLDERS
•  This  report  entails  a  detailed  quantitative  market  analysis  from  2018  to  2026  to  identify  the  prevailing  opportunities  along  with  strategic  assessment  of  the  global  cancer  therapeutics  market.

•  Cancer  therapeutics  market  size  and  market  estimations  are  based  on  a  comprehensive  analysis  of  the  applications,  top  selling  drugs,  and  developments  in  the  industry.

•  An  in-depth  analysis  based  on  region  assists  to  understand  the  regional  market  and  facilitate  the  strategic  business  planning.

•  The  development  strategies  adopted  by  the  key  market  players  are  enlisted  to  understand  the  competitive  scenario  of  the  market.

KEY  MARKET  SEGMENTS
•  By  Application
o  Blood  Cancer
o  Lung  Cancer
o  Colorectal  Cancer
o  Prostate  Cancer
o  Breast  Cancer
o  Cervical  Cancer
o  Head  and  Neck  Cancer
o  Glioblastoma
o  Malignant  Meningioma
o  Mesothelioma
o  Melanoma
o  Others
•  By  Top  Selling  Drugs
o  Revlimid
o  Avastin
o  Herceptin
o  Rituxan
o  Opdivo
o  Gleevec
o  Velcade
o  Imbruvica
o  Ibrance
o  Zytiga
o  Alimta
o  Xtandi
o  Tarceva
o  Perjeta
o  Temodar
o  Others
•  By  Region
o  North  America
?  U.S.

?  Canada
o  Europe
?  Germany
?  France
?  UK
?  Italy
?  Spain
?  Rest  of  Europe
o  Asia-Pacific
?  Japan
?  China
?  India
?  Australia
?  South  Korea
?  Taiwan
?  Rest  of  Asia-Pacific
o  LAMEA
?  Latin  America
?  Middle-East
?  Africa
The  list  of  key  players  operating  in  this  market  include:
•  F.  Hoffmann-La  Roche  AG
•  Bristol-Myers  Squibb  Company
•  AbbVie,  Inc.

•  Johnson  &  Johnson
•  Celgene  Corporation
•  Astellas  Pharma,  Inc.

•  Pfizer,  Inc.

•  Novartis  AG
•  Merck  KGaA
•  Eli  Lilly  and  Company
The  other  players  included  in  the  value  chain  analysis  (and  not  included  in  the  report)  include:
•  AstraZeneca  plc
•  Bayer  AG
•  Takeda  Pharmaceutical  Company  Limited
 
Narcolepsy  is  characterized  by  several  symptoms  that  include  cataplexy,  excessive  daytime  sleepiness,  hallucinations,  and  sleep  paralysis.  In  addition,  patients  suffering  from  narcolepsy  experience  automatic  behaviors  such  as  eating,  walking,  or  driving,  in  a  dazed  manner.  Symptoms  differ  from  patient  to  patient,  and  are  diagnosed  between  the  ages  of  7  and  25.  The  global  narcolepsy  drugs  market  accounted  for  around  $2,429  million  in  2018,  and  is  expected  to  reach  $5,360  million  by  2026,  registering  a  CAGR  of  10.3%  from  2019  to  2026.


Although  narcolepsy  is  a  rare  and  underdiagnosed  chronic  condition,  many  cases  have  been  reported  of  the  people  affected  by  this  disease.  It  was  estimated  that  more  than  1  in  2,000  people  in  the  U.S.  were  affected  by  narcolepsy  in  2012.  Increase  in  severity  of  the  disease  and  rise  in  the  number  of  people  being  affected  by  narcolepsy  are  some  of  the  key  driving  factors  of  the  market.  Furthermore,  the  availability  of  reimbursement  for  FDA-approved  prescription  medicines  is  expected  to  fuel  the  demand  for  these  drugs.  However,  lack  of  awareness  regarding  the  diagnosis  and  treatment  availability  hinders  the  market  growth.  Conversely,  increase  in  the  number  of  programs  by  various  organizations  to  spread  awareness  regarding  the  importance  of  early  narcolepsy  diagnosis  is  anticipated  to  offer  lucrative  opportunities  for  market  expansion.


The  global  narcolepsy  drugs  market  is  segmented  based  on  disease  type,  therapeutics  type,  and  geography.  Depending  on  disease  type,  the  market  is  categorized  into  daytime  extreme  sleepiness,  cataplexia,  and  others.  By  therapeutics  type,  it  is  segregated  into  central  nervous  system  stimulants,  tricyclic  antidepressants,  sodium  oxybate,  selective  serotonin  reuptake  inhibitor,  and  others.  Region  wise,  the  market  is  examined  across  North  America,  Europe,  Asia-Pacific,  and  LAMEA.


Comprehensive  competitive  analysis  and  profiles  of  major  market  players  such  as  Ligand  Pharmaceuticals,  Addrenex  Pharmaceuticals,  Shire  Plc.,  Teva  Pharmaceutical  Industries  Ltd.,  Arena  Pharmaceuticals,  Jazz  Pharmaceuticals  Plc.,  Bioprojet,  and  Graymark  Healthcare,  Inc.  have  been  provided  in  this  report.  Product  launch  and  technological  advancements  are  the  few  strategies  adopted  by  the  key  players  of  the  global  narcolepsy  drugs  market.


KEY  BENEFITS  FOR  STAKEHOLDERS

?  This  report  highlights  the  market  dynamics  to  understand  the  global  narcolepsy  drugs  market  and  capitalize  on  the  prevailing  opportunities.

?  Quantitative  analysis  of  the  current  market  and  forecasts  assists  stakeholders  to  design  business  strategies  accordingly.  
?  Porter's  five  forces  analysis  examines  the  competitive  market  structure  and  provides  a  deeper  understanding  of  the  influencing  factors  for  entry  and  expansion.

?  Pin-point  analysis  of  geographical  segments  offers  identification  of  most  profitable  segments  to  capitalize  on.


KEY  MARKET  SEGMENTS
•  By  Disease  Type  
o  Daytime  Extreme  Sleepiness
o  Cataplexia
o  Others
•  By  Therapeutics  Type
o  Central  Nervous  System  Stimulants
o  Tricyclic  Antidepressants
o  Sodium  Oxybate
o  Selective  Serotonin  Reuptake  Inhibitor
o  Others
•  By  Region
o  North  America
•  U.S.

•  Canada
•  Mexico
o  Europe
•  Germany
•  France
•  Spain
•  Italy
•  UK
•  Rest  of  Europe
o  Asia-Pacific
•  Australia
•  Japan
•  India
•  China
•  Rest  of  Asia-Pacific
o  LAMEA
•  Brazil
•  Saudi  Arabia
•  South  Africa
•  Rest  of  LAMEA

KEY  MARKET  PLAYERS  
•  Ligand  Pharmaceuticals
•  Addrenex  Pharmaceuticals
•  Shire  Plc.

•  Teva  Pharmaceutical  Industries  Ltd.

•  Arena  Pharmaceuticals
•  Jazz  Pharmaceuticals  Plc.

•  Bioprojet
•  Graymark  Healthcare,  Inc.
 
The  safety  needles  market  accounted  for  $1,609  million  in  2018,  and  is  expected  to  reach  $3,009  million  by  2026,  registering  a  CAGR  of  8.1%  from  2019  to  2026.  
Safety  needle  is  a  hollow,  cylindrical  needle  bearing  a  puncturing  point  at  the  tip,  which  is  attached  to  a  syringe.  It  is  used  across  medical  settings  in  different  applications  such  as  drug  delivery,  vaccination,  and  blood  specimen  collection  for  examination  and  research  purposes.  These  needles  are  referred  to  as  safety  needles  due  to  the  extra  function  they  perform.  For  instance,  these  safety  devices  are  equipped  with  sheaths  used  to  cover  the  needle  to  prevent  needlestick  injuries,  which  can  cause  lethal  infections.  Moreover,  these  needles  use  different  systems  to  provide  safety  against  needlestick  injuries  such  as  active  safety  needles  require  manual  activation,  whereas  passive  safety  needles  do  not  require  any  activation  and  are  automatic.

The  factors  that  boost  the  growth  of  safety  needles  market  include  surge  in  prevalence  of  needlestick  injuries  and  increase  in  cases  of  chronic  diseases  &  infections.  Moreover,  other  factors  that  contribute  toward  the  growth  of  the  market  include  favorable  government  initiatives  related  to  the  use  of  safety  needles.  However,  factors  such  as  high  price  of  these  needles  and  availability  of  alternative  modes  of  drug  delivery  restrain  the  growth  of  the  market.  On  the  contrary,  high  growth  potential  in  emerging  economies  is  expected  to  create  lucrative  opportunities  for  the  market  during  the  forecast  period.  
The  global  safety  needle  market  is  segmented  based  on  product,  end  user,  and  region.  On  the  basis  of  product,  the  market  is  bifurcated  into  active  safety  needles  and  passive  safety  needles.  By  end  user,  it  is  categorized  into  hospitals  &  ambulatory  surgery  centers,  diabetic  patients,  family  practice,  psychiatry,  and  others.  Region  wise,  it  is  analyzed  across  North  America  (U.S.,  Canada,  and  Mexico),  Europe  (Germany,  UK,  Italy,  Spain,  France,  Czech  Republic,  Republic  of  Moldova,  Poland,  Hungary,  Romania,  Russia,  Slovakia,  Ukraine,  Greece,  and  rest  of  Europe),  Asia-Pacific  (Japan,  China,  Australia,  India,  South  Korea,  Taiwan,  and,  rest  of  Asia-Pacific)  and  LAMEA  (Brazil,  South  Africa,  Saudi  Arabia,  UAE,  Qatar,  Lebanon,  Jordan,  and  rest  of  LAMEA).

KEY  BENEFITS  FOR  STAKEHOLDERS
• This  report  entails  a  detailed  quantitative  analysis  along  with  the  current  global  safety  needles  market  trends  from  2019  to  2026  to  identify  the  prevailing  opportunities  along  with  the  strategic  assessment.

• The  market  size  and  estimations  are  based  on  a  comprehensive  analysis  of  key  developments  in  the  industry.  
• A  qualitative  analysis  based  on  innovative  products  facilitates  strategic  business  planning.

• The  development  strategies  adopted  by  the  key  market  players  are  enlisted  to  understand  the  competitive  scenario  of  the  market

Key  Market  Segments
• By  Product
o Active  Safety  Needles  
o Passive  Safety  Needles  
• By  End  User
o Hospitals  &  Ambulatory  Surgery  Centers
o Diabetic  Patients
o Family  Practice
o Psychiatry
o Others
o Others

• By  Region
o North  America
? U.S.

? Canada
? Mexico
o Europe
? Germany  
? France  
? UK  
? Italy
? Spain
? Czech  Republic
? Republic  of  Moldova
? Poland
? Hungary
? Romania
? Russia
? Slovakia
? Ukraine
? Greece
? Rest  of  Europe
o Asia-Pacific
? Japan  
? China  
? India  
? Australia  
? South  Korea
? Taiwan
? Rest  of  Asia-Pacific
o LAMEA
? Brazil  
? Saudi  Arabia  
? South  Africa
? UAE
? Qatar
? Lebanon
? Jordan
? Rest  of  LAMEA

List  of  key  players  profiled  in  the  report:
• B.  Braun  Melsungen  AG
• Becton,  Dickinson  and  Company
• Cardinal  Health
• Johnson  &  Johnson  (Ethicon  Inc.)
• Nipro  Corporation
• Novo  Nordisk  A/S
• Retractable  Technologies,  Inc.

• Smiths  Group  Plc.

• Terumo  Corporatio
• Vygon  SA



LIST  of  OTHER  PLAYERS  IN  THE  VALUE  CHAIN  (These  players  are  not  profiled  in  the  report.  The  same  will  be  included  on  request)
• DeRoyal  Industries
• Hindustan  Syringes  &  Medical  Devices  Limited
• Hi-Tech  Syringes
The  global  health  insurance  market  was  valued  at  $1,682  million  in  2018,  and  is  estimated  to  reach  $2,388  million  by  2026,  registering  a  CAGR  of  4.4%  from  2019  to  2026.

health  insurance  covers  various  Health  expenses,  including  the  routine  of  health  examinations,  unforeseen  illnesses  or  injuries,  inpatient  &  outpatient  surgery,  specialist  referral  visits,  and  prescription  medications  of  insured  people.  health  insurance  provides  compensation  for  such  medical  expenses  that  may  incur,  owing  to  sickness  or  injury  to  the  insured  people  in  exchange  for  a  monthly  premium  or  a  payroll  tax  to  provide  the  Health  benefits.  
Health  insurance  provides  coverage  to  quick  suffering  diseases  with  a  minimum  premium  amount.  Various  governments  across  the  globe  provide  subsidies  for  people  who  cannot  afford  to  pay  the  premium  for  health  insurance.  However,  some  public  health  insurance  providers  do  not  cover  expensive  diseases  such  as  cancer  and  dental  recovery.

Increase  in  the  prevalence  of  chronic  diseases  such  as  cardiovascular  disease,  cancer  and  diabetes  boost  the  growth  of  the  global  health  insurance  market.  In  addition,  the  major  factor  that  drives  the  growth  of  the  market  includes  rise  in  Health  expenses.  Furthermore,  the  mandatory  provision  of  health  insurance  for  private  and  public  sector  employees  propel  the  market  growth.  However,  term  and  condition  mentioned  in  health  insurance  policies,  such  as  limitation  of  reimbursement  in  certain  hospitals  &  clinics  and  elimination  of  insurance  coverage  for  expensive  treatments  are  expected  to  hamper  the  market  growth.  On  the  contrary,  introduction  of  advanced  health  system  is  expected  to  serve  as  a  remunerative  opportunity  for  market  expansion.  
The  global  health  insurance  is  studied  on  the  basis  of  provider,  insurance  type,  coverage  type  demographics,  network,  and  region.  By  provider,  the  market  is  divided  into  private  providers  and  public  providers.  Depending  on  insurance,  it  is  categorized  into  disease  insurance,  medical  insurance,  and  income  protection  insurance.  As  per  coverage  type,  it  is  divided  into  lifetime  coverage  and  term  coverage.  According  to  demographics,  it  is  fragmented  into  minors,  adults,  and  senior  citizen.  On  the  basis  of  network,  it  is  segregated  into  preferred  provider  organizations  (PPOs),  point  of  services  (POS),  health  maintenance  organizations  (HMOs),  and  exclusive  provider  organizations  (EPOs).  In-depth  analysis  of  the  health  insurance  market  is  provided  for  North  America,  Europe,  Asia-Pacific,  and  LAMEA.


KEY  MARKET  BENEFITS  FOR  STAKEHOLDERS
• This  report  entails  a  detailed  quantitative  analysis  of  the  current  market  trends  from  2019  to  2026  to  identify  the  prevailing  opportunities.

• Market  estimations  are  based  on  a  comprehensive  analysis  of  the  key  developments  in  the  industry.

• In-depth  analysis  based  on  region  assists  to  understand  the  regional  market  to  assist  in  strategic  business  planning.

• The  development  strategies  adopted  by  key  manufacturers  are  enlisted  to  understand  the  competitive  scenario  of  the  market.

KEY  MARKET  SEGMENTS
By  Provider
• Private  Providers
• Public  Providers
By  Insurance  Type
• Disease  Insurance
• Medical  Insurance  
• Income  Protection  Insurance
By  Coverage  Type  
• Lifetime  Coverage  
• Term  Coverage
By  Demographics  
• Minors
• Adults
• Senior  Citizen
By  Network  
• Preferred  Provider  Organizations  (PPOs)
• Point  of  Services  (POS)
• Health  Maintenance  Organizations  (HMOs)
• Exclusive  Provider  Organizations  (EPOs)
By  Region
• North  America
o U.S.

o Canada
o Mexico
• Europe
o Germany
o France
o United  Kingdom
o Italy
o Spain
o Others
• Asia-Pacific
o Japan
o China
o Australia
o India
o South  Korea
o Others
• LAMEA
o Brazil
o Saudi  Arabia
o South  Africa
o Others

KEY  PLAYERS  PRofILED
• Allianz  Group
• Assicurazioni  Generali  S.p.A
• AIA  Group  Limited  
• Anthem,  Inc.

• AXA  Equitable  Life  Insurance  Company  
• China  Life  Insurance  Company  Limited
• Munich  Re
• Ping  An  Insurance  (Group)  Company  of  China,  Ltd.

• State  Farm  Group
• Zurich  Insurance  Group.

The  other  players  of  the  health  insurance  market  in  value  chain  analysis  (not  included  in  this  report)  are
• Berkshire  Hathaway  Inc.

• Prudential  Plc.

• Nippon  Life  Insurance  Company
• Dai-ichi  Life  Holdings,  Inc.

• Kaiser  Foundation  Group  of  Health  Plans
• Berkshire  Hathaway  Inc.

• New  York  Life  Insurance  Company
• Life  Insurance  Corporation  of  India
The  China  oncology  drugs  market  was  valued  at  $6,498.2  million  in  2018  and  is  projected  to  reach  $12,688.7  million  by  2026,  registering  a  CAGR  of  8.7%  from  2019  to  2026.  Cancer  is  the  second  leading  cause  of  death  globally  and  is  responsible  for  an  estimated  9.6  million  deaths  in  2018.  Globally,  about  1  in  6  deaths  is  due  to  cancer  according  to  the  data  published  by  WHO.  Being  the  most  populous  country  in  the  world,  cancer  rates  are  significantly  rising  in  China.  As  per  Global  Cancer  Observatory  in  2018,  the  number  of  new  cancer  cases  registered  each  year  in  China  are  4,285,033.  Amongst  which,  lung  cancer  constitutes  18.1%;  colorectum  cancer  is  about  12.2%;  stomach  cancer  is  approximately  10.6%;  liver  cancer  constitutes  9.2%;  breast  cancer  comprises  of  8.6%  and  41.1%  other  cancers.  The  population  of  China  accounts  for  19.3%  of  the  global  population,  and  the  incidence  rate  of  cancer  accounts  for  22%  of  global  cancer  incidence,  ranking  first  in  the  world.  Cancer  deaths  in  China  account  for  about  27%  of  global  cancer  deaths.  Cancer  mortality  in  China  is  also  higher  than  the  global  average  of  17%.  

Rise  in  incidence  of  various  cancer  conditions,  aging  population,  westernized  diet,  shift  to  sedentary  lifestyle,  and  surge  in  tobacco  smoke  exposure  due  to  urbanization  in  China  are  the  key  factors  that  drive  the  growth  of  the  cancer.  This  in  turn  boosts  the  growth  of  the  China  oncology  drugs  market.  Furthermore,  rise  in  cancer  awareness  and  increase  in  availability  of  cancer  drugs  are  expected  to  boost  the  market  growth.  However,  the  use  of  traditional  Chinese  medicine  (TCM)  to  cure  cancer  and  high  cost  involved  in  new  drug  development  coupled  with  threat  of  failure  &  adverse  effects  associated  with  cancer  drugs  therapies  are  expected  to  restrain  the  growth  of  the  market.  Conversely,  high  potential  of  emerging  economies  and  increase  in  number  of  pipeline  products  are  expected  to  provide  new  opportunities  for  market  players  in  future.  

The  China  oncology  drugs  market  is  segmented  based  on  drug  class  type  and  indication.  Depending  on  drug  class  type,  the  market  is  divided  into  chemotherapy,  targeted  therapy,  immunotherapy,  and  hormonal  therapy.  By  indication,  it  is  categorized  into  blood  cancer,  breast  cancer,  gastrointestinal  cancer,  prostate  cancer,  lung  cancer,  skin  cancer,  ovarian  cancer,  cervical  cancer,  kidney  cancer,  and  other  cancers.


KEY  MARKET  BENEFITS
• This  report  entails  a  detailed  quantitative  analysis  along  with  the  current  China  oncology  drugs  market  trends  from  2019  to  2026  to  identify  the  prevailing  opportunities  along  with  the  strategic  assessment.

• The  market  forecast  is  studied  from  2019  to  2026.

• The  market  size  and  estimations  are  based  on  a  comprehensive  analysis  of  key  developments  in  the  industry.

• A  qualitative  analysis  based  on  innovative  products  facilitates  strategic  business  planning.

• The  development  strategies  adopted  by  the  key  market  players  are  enlisted  to  understand  the  competitive  scenario  of  the  market.

Key  market  segments
By  Drug  Class  Type
• Chemotherapy
• Targeted  Therapy
• Immunotherapy  Therapy
• Hormonal  Therapy
By  Indication
• Blood  Cancer
• Breast  Cancer
• Gastrointestinal  Cancer
• Prostate  Cancer
• Lung  Cancer
• Skin  Cancer
• Ovarian  Cancer
• Cervical  Cancer    
• Kidney  Cancer  
• Other  Cancers  
LIST  of  KEY  PLAYERS  PRofILED  IN  THE  REPORT
• AbbVie  Inc.

• Astellas  Pharma  Inc.

• AstraZeneca  PLC
• Bristol-Myers  Squibb  Company
• Celgene  Corporation
• F.  Hoffmann-La  Roche  Ltd.

• Johnson  &  Johnson
• Shanghai  Junshi  Biosciences  Co.,  Ltd.

• Beigene
• Jiangsu  Hengrui  Medicine  Co.,  Ltd
The  Japan  oncology  drugs  market  accounted  for  $9,405  million  in  2018,  and  is  expected  to  reach  $14,109  million  by  2026,  registering  a  CAGR  of  5.2%  from  2019  to  2026.  
Cancer  is  a  serious  medical  condition  marked  by  the  presence  of  tumor  cells  present  in  the  body.  The  formation  of  tumor  cells  take  place  when  the  normal  cells  grow  at  an  abnormal  rate.  Moreover,  these  tumor  cells  also  have  the  ability  to  spread  to  other  parts  of  the  body  through  blood  and  lymphatic  system.  In  addition,  cancer  has  different  stages  which  are  based  on  the  growth  pattern  of  tumor.  Therefore,  the  treatment  of  cancer  differs  depending  on  the  stage  of  cancer.  Chemotherapy  drugs  are  mostly  employed  in  the  treatment  of  early  stage  cancers  and  similarly  targeted  therapy  and  immunotherapy  drugs  are  generally  preferred  in  the  treatment  of  late  stage  cancers.

Surge  in  research  related  to  new  drug  discovery  for  cancer  treatment,  rise  in  incidence  of  cancer  in  Japan,  and  increase  in  healthcare  expenditure  boost  the  growth  of  Japan  oncology  drugs  market.  Moreover,  rise  in  awareness  related  to  early  diagnosis  of  cancer  leading  to  rise  in  demand  of  oncology  drugs  for  treatment  is  another  factor  that  fuels  the  growth  of  the  market  in  Japan.  Furthermore,  surge  in  geriatric  population  also  contributes  to  the  growth  of  the  market  as  the  elderly  are  more  prone  to  certain  cancer  such  as  prostate  cancer.  In  addition,  rise  in  number  of  pipeline  products  is  expected  to  provide  lucrative  opportunities  during  the  forecast  period.  Conversely,  stringent  approval  process  of  oncology  drugs  in  Japan  hinders  the  growth  of  market.

The  Japan  oncology  drugs  market  size  is  studied  based  on  segments,  drug  class  type  and  indication.  Based  on  drug  class  type,  the  market  is  divided  into  chemotherapy,  targeted  therapy,  immunotherapy,  hormonal  therapy.  By  indication,  it  is  categorized  into  blood  cancer,  breast  cancer,  gastrointestinal  cancer,  prostate  cancer,  lung  cancer,  skin  cancer,  ovarian  cancer,  cervical  cancer,  kidney  cancer  and  others.


KEY  BENEFITS  FOR  STAKEHOLDERS
• The  study  provides  an  in-depth  analysis  of  the  market  along  with  the  current  trends  and  future  estimations  to  elucidate  the  imminent  investment  pockets.

• It  offers  a  quantitative  analysis  from  2018  to  2026,  which  is  expected  to  enable  the  stakeholders  to  capitalize  on  the  prevailing  market  opportunities.  
• The  profiles  and  growth  strategies  of  the  key  players  are  thoroughly  analyzed  to  understand  the  competitive  outlook  of  the  Japan  market
• A  qualitative  analysis  based  on  innovative  products  facilitates  strategic  business  planning.


Key  Market  Segments
By  Drug  Class  Type
• Chemotherapy
• Targeted  Therapy
• Immunotherapy  (Biologic  Therapy)
• Hormonal  Therapy
By  Indication
• Blood  Cancer
• Breast  Cancer
• Gastrointestinal  Cancer
• Prostate  Cancer
• Lung  Cancer
• Skin  Cancer
• Ovarian  Cancer
• Cervical  Cancer
• Other  Cancers

List  of  key  players  profiled  in  the  report:
• Otsuka  Holdings  Co  Ltd
• Johnson  and  Johnson
• Daiichi  Sankyo  Co  Ltd
• AstraZeneca  plc
• AbbVie  Inc.

• Celgene  Corporation
• Bristol-Myers  Squibb  Company
• F.  Hoffmann-La  Roche  AG
• Astellas  Pharma  Inc.

• Takeda  Pharmaceutical  Company  Ltd

LIST  of  OTHER  PLAYERS  IN  THE  VALUE  CHAIN  (These  players  are  not  profiled  in  the  report.  The  same  will  be  included  on  request)
• Sanofi
• Amgen  Inc.

• Bayer  AG
The  global  mobile  gamma  cameras  market  size  was  $XX  million  in  2018  and  is  projected  to  reach  $XX  million  by  2026,  growing  at  a  CAGR  of  XX%  from  2019  to  2026.


Mobile  gamma  camera  system  is  an  imaging  technique  to  generate  functional  scans  of  small  and  large  organs  including  brain,  cardiac,  neurological,  breast,  thyroid,  pancreas  and  kidney  applications.  The  mobile  gamma  camera  scans  the  body  by  using  a  procedure  that  follows  injecting  a  radionucleotide  in  the  body  or  organ  and  then  recording  the  resulting  radioactivity  by  image  scanning.  In  mobile  gamma  camera  the  total  examination  time  is  ten  minutes  till  final  images.  Further,  mobile  gamma  camera  system  can  be  used  at  bedside  and  is  greater  in  clinical  practices.  Nuclear  imaging  is  performed  due  to  its  better  selectivity  and  resolution.  Thus,  it  is  vastly  used  at  the  time  of  surgery  in  the  healthcare  sector.    In  addition,  a  rise  in  number  of  applications  of  mobile  gamma  camera  devices  is  expected  to  reduce  the  costs  of  hospitalization  without  threatening  the  safety  of  patients.


The  global  mobile  gamma  cameras  market  is  experiencing  growth  owing  to  factors  such  as  advantages  of  mobile  gamma  cameras  over  traditional  gamma  cameras,  and  technological  advancements  in  expanding  the  imaging  options.  Further,  factors  such  as  rise  in  prevalence  of  chronic  diseases  in  near  future,  fuel  the  growth  of  the  global  mobile  gamma  cameras  market.  However,  side  effects  such  as  decrease  in  organ  function,  hair  loss  and  skin  burn  of  mobile  gamma  cameras  and  exposure  to  a  lethal  dose  of  gamma  radiation  are  certain  factors  which  hamper  the  growth  of  the  global  mobile  gamma  cameras  market.  On  the  contrary,  development  of  mobile  gamma  camera  is  slowly  replacing  the  conventional  cameras,  and  this  represents  the  biggest  technological  development  in  the  market  followed  by  miniaturization  and  numerous  developments  in  the  radionucleotide,  which  are  anticipated  to  create  newer  opportunities  in  the  emerging  as  well  as  the  developed  markets.


The  global  mobile  gamma  cameras  market  is  segmented  based  on  product  type,  application,  end  user,  and  region  to  provide  a  detailed  assessment  of  the  market.  Based  on  product  type,  the  market  is  classified  into  single-head  mobile  gamma  cameras,  dual-head  mobile  gamma  cameras,  triple-head  mobile  gamma  cameras,  and  handheld  mobile  gamma  camera.  Based  on  application,  the  market  is  segmented  into  cardiac  imaging,  breast  imaging,  thyroid  scanning,  kidney  scanning,  intraoperative  imaging,  and  others.  Based  on  end  user,  it  is  classified  into  hospital,  imaging  centers  &  clinics,  and  research  centers.  Based  on  region,  it  is  analyzed  across  North  America,  Europe,  Asia-Pacific,  and  LAMEA.  

KEY  BENEFITS  FOR  STAKEHOLDERS

? This  report  provides  a  detailed  quantitative  analysis  of  the  current  market  trends  and  future  estimations  from  2019  to  2028,  which  assists  to  identify  the  prevailing  market  opportunities.  
? An  in-depth  analysis  of  various  regions  is  anticipated  to  provide  a  detailed  understanding  of  the  current  trends  to  enable  stakeholders  to  formulate  region-specific  plans.

? A  comprehensive  analysis  of  the  factors  that  drive  and  restrain  the  growth  of  the  global  mobile  gamma  cameras  market  is  provided.

? An  extensive  analysis  of  various  regions  provides  insights  that  allows  companies  to  strategically  plan  their  business  moves.


KEY  MARKET  SEGMENTS
• By  Product  type
o Single-head  Mobile  Gamma  Cameras
o Dual-head  Mobile  Gamma  Cameras
o Triple-head  Mobile  Gamma  Cameras  
o Handheld  Mobile  Gamma  Camera  

• By  Application
o Cardiac  Imaging
o  Breast  Imaging
o  Thyroid  Scanning
o  Kidney  Scanning  
o  Intraoperative  Imaging  
o Other
• By  End  User
o Hospital
o Imaging  Centers  &  Clinics
o Research  Centers
• By  Region
o North  America
? U.S.

? Canada
? Mexico
o Europe
? Germany
? France
? Spain
? Italy
? UK
? Rest  of  Europe
o Asia-Pacific
? Japan
? India
? China
? South  Korea
? Rest  of  Asia-Pacific
o LAMEA
? Brazil
? Saudi  Arabia
? South  Africa
? Rest  of  LAMEA

KEY  MARKET  PLAYERS  
• Dilon  Technologies,  Inc
• General  Electric  Company  (GE  Healthcare)
• Digirad  Corporation
• DDD-Diagnostic  A/S
• GAEDE  Medizinsysteme  GmbH,
• Adolesco  AB,  MiE  GmbH
• Gamma  Medica,  Inc.  
• Crystal  Photonics  GmbH  
• Oncovision.
The  Australia  &  New  Zealand  fertility  services  market  generated  $709  million  in  2018,  and  is  projected  to  reach  $1,020  million  by  2026,  growing  at  a  CAGR  of  4.6%  from  2019  to  2026.    

Fertility  services  are  treatments  that  assist  in  treating  infertility  in  patients.  In  vitro  fertilization  (IVF),  surrogacy,  intrauterine  insemination,  and  others  are  different  forms  of  infertility  services  that  help  single  mothers,  couples  with  infertility  problems,  and  people  from  the  LGBT  community  to  procreate.

The  Australia  &  New  Zealand  fertility  services  market  is  expected  to  witness  a  substantial  growth  in  the  future,  owing  to  higher  number  of  infertility  cases,  emerging  trend  of  delayed  pregnancies  among  women,  rise  in  technological  advancements  in  fertility  procedures,  and  large  presence  of  fertility  clinics  with  trained  medical  professionals.  In  addition,  availability  of  advanced  fertility  treatments,  increase  in  disposable  income,  and  favorable  reimbursement  policies  further  augment  the  market  growth  in  Australia  &  New  Zealand.  In  addition,  recent  innovations  in  IVF  technology  with  surge  in  assisted  reproductive  technology  (ART)  success  rate  are  projected  to  boost  the  demand  for  fertility  services  in  the  future.  However,  higher  cost,  complications  associated  with  ART  treatment,  and  multiple  pregnancies  associated  with  fertility  treatments  are  projected  to  hinder  the  market  growth.  Rise  in  new  fertility  clinics  and  increase  in  same-sex  marriages  are  projected  to  offer  lucrative  growth  opportunities  in  future.  

The  Australia  &  New  Zealand  fertility  services  market  is  segmented  based  on  procedure,  service,  and  end  user.  Based  on  procedure,  the  market  is  divided  into  IVF  with  intracytoplasmic  sperm  injection  (ICSI),  intrauterine  insemination  (IUI),  IVF  without  ICSI,  surrogacy,  and  others.  Based  on  service,  it  is  categorized  into  fresh  non-donor,  frozen  non-donor,  egg  and  embryo  banking,  fresh  donor,  and  frozen  donor.  Based  on  end  user,  the  market  is  segmented  into  fertility  clinics,  hospitals,  surgical  centers,  and  clinical  research  institutes.  
 
 
KEY  BENEFITS  FOR  STAKEHOLDERS
• The  study  provides  an  in-depth  analysis  of  the  market  along  with  the  current  trends  and  future  estimations  to  elucidate  the  imminent  investment  pockets.

• It  offers  a  quantitative  analysis  from  2018  to  2026,  which  is  expected  to  enable  the  stakeholders  to  capitalize  on  the  prevailing  market  opportunities.  
• A  comprehensive  analysis  of  all  the  regions  is  provided  to  determine  the  existing  opportunities.

• The  profiles  and  growth  strategies  of  the  key  players  are  thoroughly  analyzed  to  understand  the  competitive  outlook  of  the  global  market.


KEY  MARKET  SEGMENTS
By  Procedure
o IVF  with  ICSI
o IUI
o IVF  without  ICSI
o Surrogacy
o Others

Service
o Fresh  Non-donor
o Frozen  Non-donor
o Egg  and  Embryo  Banking
o Fresh  Donor
o Frozen  Donor

End  User
o Fertility  Clinics
o Hospitals
o Surgical  Centers
o Clinical  Research  Institutes

LIST  of  KEY  PLAYERS  PRofILED  IN  THE  REPORT
• Adora  Fertility
• Care  Fertility
• City  Fertility
• Fertility  Associates  Limited
• Fertility  First
• Fertility  SA
• GENEA  LIMITED
• Monash  IVF  Group  Limited
• National  Women’s  Health
• Virtus  Health      

LIST  of  OTHER  PLAYERS  IN  THE  VALUE  CHAIN  (These  players  are  not  profiled  in  the  report.  The  same  will  be  included  on  request.)
• Demeter  Fertility
• Coastal  IVF
• Melbourne  IVF
The  Germany  IVF  market  was  valued  at  $398  million  in  2018  and  is  estimated  to  reach  $541  million  by  2026,  registering  a  CAGR  of  3.9%  during  the  analysis  period.


In  vitro  fertilization  (IVF)  is  a  process  that  includes  fertilization  of  egg  cells  outside  the  body.  It  is  one  of  the  widely  known  infertility  treatment  across  the  clinical  industry.  The  technique  is  based  on  assisted  reproductive  technology  and  is  employed  in  the  treatment  of  infertility.  The  process  involves  removing  an  ovum  (egg  or  eggs)  the  ovaries  and  facilitating  its  fertilization  with  the  help  of  a  sperm  in  a  laboratory  dish.  After  the  fertilized  egg  (zygote)  undergoes  embryo  culture  for  up  to  6  days,  it  is  implanted  in  another  or  same  woman's  uterus,  depending  on  the  conditions.  IVF  helps  achieve  pregnancy  when  other  treatments  fail.  It  is  generally  not  used  until  less  expensive  or  invasive  options  have  failed  or  been  determined  unlikely  to  work.


Subsidizing  IVF  treatments,  delayed  marriages  and  parenthood  decisions,  and  increase  in  prevalence  of  infertility  issues  are  the  factors  that  majorly  drive  the  growth  of  the  IVF  market  in  Germany.  In  addition,  as  per  National  Health  Plan  (NHP),  about  50%  of  the  treatment  cost  by  IVF  paid  for  three  cycles  is  projected  to  boost  growth  of  the  IVF  market  in  Germany.  However,  stringent  government  regulations  and  lack  of  availability  in  treatment  cycles  for  IVF  are  the  major  restraints  that  hamper  the  growth  of  the  market  in  Germany.


The  Germany  in  vitro  fertilization  market  (IVF)  is  segmented  based  on  cycle  type  and  end  user.  Based  on  cycle  type,  the  market  is  divided  into  fresh  IVF  cycles  (non-donor),  and  thawed  IVF  cycles  (non-donor).  Based  on  end  user,  the  market  is  classified  into  fertility  clinics,  hospitals,  surgical  centers,  and  clinical  research  institutes.


KEY  MARKET  BENEFITS
• The  study  provides  an  in-depth  analysis  of  the  Germany  in  vitro  fertilization  (IVF)  market  along  with  the  current  trends  and  future  estimations  to  elucidate  the  imminent  investment  pockets.

• The  report  presents  a  quantitative  analysis  of  the  market  from  2018  to  2026  to  enable  stakeholders  to  capitalize  on  the  prevailing  market  opportunities.

• An  extensive  analysis  of  the  market  based  on  application  assists  in  understanding  the  trends  in  the  industry.

• The  key  market  players  along  with  their  strategies  are  thoroughly  analyzed  to  understand  the  competitive  outlook  of  the  industry.

KEY  MARKET  SEGMENTS
Germany  In  Vitro  Fertilization  Market
By  Cycle  Type
o Fresh  IVF  Cycles  (Non-donor)
o Thawed  IVF  Cycles  (Non-donor)
By  End  User
o Fertility  Clinics
o Hospitals
o Surgical  Centers
o Clinical  Research  Institutes
LIST  of  KEY  PLAYERS  PRofILED  IN  THE  REPORT
• Heidelberg  University  Hospital
• Klinikum  Stuttgart
• DRK  Kliniken  Berlin
• University  Medical  Center  Freiburg
The  UK  IVF  market  was  valued  at  $514  million  in  2018  and  is  estimated  to  reach  $928  million  by  2026,  registering  a  CAGR  of  7.6%  during  the  analysis  period.


In-vitro-Fertilization  (IVF)  is  a  common  artificial  infertility  treatment  performed  in  the  laboratory.  The  treatment    involves  removing  an  ova  (egg  or  eggs)  or  ovum  from  the    ovaries  and  allowing  sperm  to  fertilize  them  in  a  laboratory  dish.  It  is  a  form  of  assisted  reproductive  technology  based  fertility  treatment  across  the  clinical  industry.  The  process  involves  five  major  steps  such  as  stimulation,  egg  retrieval,  insemination  &  fertilization,  embryo  culture,  and  embryo  transfer,  which  is  completed  over  a  course  of  several  months.  After  the  fertilized  egg  (zygote)  undergoes  embryo  culture  for  up  to  6  days,  it  is  implanted  in  another  or  same  woman's  uterus.  In  vitro  fertilization  can  help  conceive  when  other  natural  treatments  have  failed.


The  UK  invitro  fertilization  market  is  on  the  rise  owing  to  increase  in  awareness  about  assisted  reproductive  technology,  favorable  regulations  for  IVF,  and  commercialization  of  three-parent  IVF  procedures.  In  addition,  rise  in  awareness  about  assisted  reproductive  technology  is  expected  to  boost  the  UK  IVF  market.  However,  ethical  considerations  by  social  and  religious  organizations,  and  cost  of  the  treatment  are  expected  to  hinder  the  growth  of  the  IVF  market  in  the  UK.  However,  involvement  of  social  and  religious  organizations  for  revaluation  of  the  IVF  legislation  in  the  UK  hinders  the  growth  of  the  market.  Furthermore,  surge  in  technical  advancements  related  IVF  technique  is  projected  to  provide  lucrative  opportunities  during  the  forecast  period.


The  UK  in  vitro  fertilization  market  (IVF)  is  segmented  based  on  cycle  type,  and  end  user.  Based  on  cycle  type,  the  market  is  divided  into  fresh  IVF  cycles  (non-donor),  thawed  IVF  cycles  (non-donor),  and  donor  egg  IVF  cycles.  Based  on  end  user,  the  market  is  classified  into  fertility  clinics,  hospitals,  surgical  centers,  and  clinical  research  institutes.



KEY  MARKET  BENEFITS
• The  study  provides  an  in-depth  analysis  of  the  UK  in  vitro  fertilization  (IVF)  market  along  with  the  current  trends  and  future  estimations  to  elucidate  the  imminent  investment  pockets.

• The  report  presents  a  quantitative  analysis  of  the  market  from  2018  to  2026  to  enable  stakeholders  to  capitalize  on  the  prevailing  market  opportunities.

• An  extensive  analysis  of  the  market  based  on  application  assists  in  understanding  the  trends  in  the  industry.

• The  key  market  players  along  with  their  strategies  are  thoroughly  analyzed  to  understand  the  competitive  outlook  of  the  industry.

KEY  MARKET  SEGMENTS
UK  In  Vitro  Fertilization  Market
By  Cycle  Type
o Fresh  IVF  Cycles  (non-donor)
o Thawed  IVF  Cycles  (non-donor)
o Donor  Egg  IVF  Cycles
By  End  User
o Fertility  Clinics
o Hospitals
o Surgical  Centers
o Clinical  Research  Institutes
LIST  of  KEY  PLAYERS  PRofILED  IN  THE  REPORT
• The  Lister  Fertility  Clinic
• The  Bridge  Centre
• Chelsea  and  Westminster  Hospital  (Assisted  Conception  Unit)
The  near  infrared  imaging  market  accounted  for  $271  million  in  2018,  and  is  expected  to  reach  $375  million  by  2026,  registering  a  CAGR  of  4.1%  from  2019  to  2026.  
Near  infrared  (NIR)  is  a  sub-division  of  the  infrared  band  of  the  electromagnetic  spectrum  having  wavelength  ranging  from  0.7  to  1.4  microns,  which  is  very  close  to  human  vision.  NIR  imaging  technique  involves  the  use  of  near  infrared  light  to  obtain  images  of  tissues.  These  systems  rely  on  fluorescent  dye,  which  is  administered  to  obtain  fluorophore  emission.  These  emissions  are  captured  by  an  imaging  system  and  camera.  This  further  produces  real  time  images  of  the  tissues.  It  is  advantageous  over  other  techniques  since  it  provides  better  resolution  and  is  less  harmless  to  patients.  NIR  Imaging  can  be  helpful  in  diagnosing  breast  cancer,  depression,  Alzheimer’s  disease,  and  schizophrenia.  Near  infrared  imaging  is  used  as  a  replacement  for  far  infrared  and  thermal  vision.  It  is  advantageous  over  thermal  vision  since  thermal  vision  can  only  absorb  heat  and  does  not  product  clear  images.

Rise  in  number  of  surgical  procedures  worldwide  for  cancer  surgery,  gastrointestinal  surgery,  and  cardiovascular  surgery,  plastic/reconstructive  surgeries  coupled  with  surge  in  prevalence  of  target  diseases  such  as  lung  cancer,  breast  cancer,  colon  cancer,  and  prostate  cancer;  increasing  prevalence  of  chronic  diseases  and  neurological  disorders,  are  responsible  for  driving  the  growth  of  near  infrared  imaging  market.  In  addition,  surge  in  adoption  of  NIR  imaging  across  the  globe,  rise  in  geriatric  population  and  health  awareness  in  the  emerging  economies  are  the  prime  growth  factor  for  the  growth  of  global  near  infrared  imaging  market.  However,  high  availability  of  other  alternative  imaging  techniques  and  high  price  of  infrared  detectors  may  restrict  the  global  near  infrared  imaging  market.

The  near  infrared  imaging  market  is  segmented  based  on  product,  application,  indication,  end  user,  and  region  to  provide  a  detailed  assessment  of  the  market.  Based  on  product,  the  market  is  divided  into  near  infrared  fluorescence  imaging  systems  and  near  infrared  fluorescence  &  bioluminescence  imaging  systems.  Based  on  application,  the  near  infrared  imaging  market  is  classified  into  pre-clinical  imaging,  medical  imaging  and  clinical  imaging.  Based  on  indication,  the  near  infrared  imaging  market  is  segmented  into  cancer  surgeries,  cardiovascular  surgeries,  gastrointestinal  surgeries,  plastic/reconstructive  surgeries,  and  others.  Based  on  end  user,  the  market  is  divided  into  hospitals  and  clinics,  research  laboratories  and  others.  Based  on  region,  the  near  infrared  imaging  market  size  is  analyzed  across  North  America,  Europe,  Asia-Pacific,  and  LAMEA.

KEY  BENEFITS  FOR  STAKEHOLDERS
• This  report  entails  a  detailed  quantitative  analysis  along  with  the  current  global  near  infrared  imaging  market  trends  from  2019  to  2026  to  identify  the  prevailing  opportunities  along  with  the  strategic  assessment.

• The  market  size  and  estimations  are  based  on  a  comprehensive  analysis  of  key  developments  in  the  industry.  
• A  qualitative  analysis  based  on  innovative  products  facilitates  strategic  business  planning.

• The  development  strategies  adopted  by  the  key  market  players  are  enlisted  to  understand  the  competitive  scenario  of  the  market

Key  Market  Segments
• By  Product
o Near  Infrared  Fluorescence  Imaging  Systems
o Near  Infrared  Fluorescence  &  Bioluminescence  Imaging  Systems
• By  Application
o Pre-clinical  Imaging
o Medical  Imaging  (Diagnostic  and  Surgeries)
o Clinical  Imaging
• By  Indication
o Cancer  Surgeries
o Cardiovascular  Surgeries
o Gastrointestinal  Surgeries
o Plastic/Reconstructive  Surgeries
o Others
• By  End  User
o Hospitals  &  Clinics
o Research  Laboratories
o Others
• By  Region
o North  America
? U.S.

? Canada
? Mexico
o Europe
? Germany  
? France  
? UK  
? Italy
? Spain
? Rest  of  Europe
o Asia-Pacific
? Japan  
? China  
? India  
? Australia  
? South  Korea
? Rest  of  Asia-Pacific
o LAMEA
? Brazil  
? Saudi  Arabia  
? South  Africa
? Rest  of  LAMEA

List  of  key  players  profiled  in  the  report:
• Carl  Zeiss  AG
• Danaher  Corporation  (Leica  Microsystems)
• Hamamatsu  Photonics  K.K.

• Karl  Storz  SE  &  Co.  KG
• Li-Cor,  Inc.

• Medtronic  plc.

• PerkinElmer  Inc.

• Quest  Innovations  B.V.  (Quest  Medical  Imaging  B.V.)
• Shimadzu  Corporation
• Stryker  Corporation  

LIST  of  OTHER  PLAYERS  IN  THE  VALUE  CHAIN  (These  players  are  not  profiled  in  the  report.  The  same  will  be  included  on  request)
• Fluoptics
• Mizuho
• Olympus  
• Hitachi,  Ltd.  
The  global  beta-lactam  and  beta-lactamase  inhibitors  market  size  was  $27,126  million  in  2018,  and  is  projected  to  reach  $34,170  million  by  2028,  growing  at  a  CAGR  of  2.3%  from  2019  to  2028.


Beta-lactam  and  beta-lactamase  inhibitors  is  a  most  important  type  of  antibacterial  agent  used  for  fighting  bacterial  infections.  In  addition,  these  are  used  to  kill  or  prevent  the  growth  of  microorganisms.  Based  on  the  molecular  structure,  beta-lactam  and  beta-lactamase  inhibitors  are  drug  classified  into  penicillin,  cephalosporin,  carbapenem,  monobactam,  and  combination.


There  is  an  increase  in  the  demand  for  beta-lactam  and  beta-lactamase  inhibitors,  owing  to  increased  consumption  in  low-  and  middle-income  countries  (LMICs)  and  rise  in  prevalence  of  infectious  diseases.  In  addition,  development  of  novel  approaches  for  new  beta-lactam  and  beta-lactamase  inhibitors  for  treating  bacterial  infections  and  a  large  number  of  clinical  trials  further  drive  the  market  growth.  However,  development  of  antibiotic  resistance,  driven  by  misuse  of  beta-lactam  and  beta-lactamase  inhibitors  and  the  time  taken  for  the  regulatory  approval  is  projected  to  impede  the  market  growth.  On  the  contrary,  discovery  of  advanced  prospect  molecules  and  novel  combination  therapies  to  treat  antibiotic-resistant  microbial  infections  are  expected  to  offer  significant  profitable  opportunities  for  the  market  players.


The  global  beta-lactam  and  beta-lactamase  inhibitors  market  is  segmented  based  on  drug  class,  disease,  route  of  administration,  and  region.  Based  on  the  drug  class,  the  market  is  classified  into  penicillin,  cephalosporin,  carbapenem,  monobactam,  and  combination.  Combination  segment  is  further  categorized  into  penicillin/beta  lactamase  inhibitors,  cephalosporins/beta  lactamase  inhibitors,  and  carbapenems/beta  lactamase  inhibitors.  Depending  on  the  disease  segment,  the  market  is  divided  into  urinary  tract  infection  (excluding  cUTI),  respiratory  infection,  skin  infection,  complicated  urinary  tract  infection  (cUTI),  complicated  intra-abdominal  infections  (cIAI),  nosocomial  pneumonia,  blood  stream  infection,  and  other  diseases.  Nosocomial  pneumonia  segment  is  further  divided  into  hospital  acquired  pneumonia,  ventilator  associated  pneumonia,  and  other  nosocomial  pneumonia.  Based  on  route  of  administration,  the  market  is  classified  into  oral,  intravenous,  and  others.  Based  on  region,  the  market  is  studied  across  North  America,  Europe,  Asia-Pacific,  and  LAMEA.


KEY  BENEFITS  FOR  STAKEHOLDERS

? This  report  provides  a  detailed  quantitative  analysis  of  the  current  market  trends  and  future  estimations  from  2019  to  2028,  which  assists  to  identify  the  prevailing  market  opportunities.  
? An  in-depth  analysis  of  various  regions  is  anticipated  to  provide  a  detailed  understanding  of  the  current  trends  to  enable  stakeholders  to  formulate  region-specific  plans.

? A  comprehensive  analysis  of  the  factors  that  drive  and  restrain  the  growth  of  the  global  beta-lactam  and  beta-lactamase  inhibitors  market  is  provided.

? An  extensive  analysis  of  various  regions  provides  insights  that  allow  companies  to  strategically  plan  their  business  moves.


KEY  MARKET  SEGMENTS
• By  Drug  Class
o Penicillin
o Cephalosporin
o Carbapenem
o Monobactam
o Combination
? Penicillin/Beta  Lactamase  Inhibitors
? Cephalosporins/Beta  Lactamase  Inhibitors
? Carbapenems/Beta  Lactamase  Inhibitors
• By  Disease
o Urinary  Tract  Infection  (excluding  cUTI)
o Respiratory  Infection
o Skin  Infection
o Complicated  Urinary  Tract  Infection  (cUTI)
o Complicated  Intra-Abdominal  Infections  (cIAI)
o Nosocomial  Pneumonia
? Hospital  Acquired  Pneumonia
? Ventilator  Associated  Pneumonia
? Other  Nosocomial  Pneumonia
o Blood  Stream  Infection
o Other  Diseases
• By  Route  of  Administration
o Oral
o Intravenous
o Others
• By  Region
o North  America
? U.S.

? Canada
? Mexico
o Europe
? Germany
? France
? Spain
? Italy
? UK
? Rest  of  Europe
o Asia-Pacific
? Japan
? India
? China
? South  Korea
? Thailand
? Taiwan
? Vietnam
? Rest  of  Asia-Pacific
o LAMEA
? Brazil
? Saudi  Arabia
? South  Africa
? Rest  of  LAMEA
KEY  MARKET  PLAYERS  
• Abbott  Laboratories
• Allergan  Plc.

• F.  Hoffmann-La  Roche  Ltd.

• GlaxoSmithKline  plc
• Merck  &  Co.  Inc.

• Mylan  N.V.

• Novartis  International  AG  (Sandoz)
• Pfizer  Inc.

• Sanofi
• Teva  Pharmaceutical  Industries  Ltd.


The  other  players  in  the  value  chain  (profiles  not  included  in  the  report)  
• Hikma  Pharmaceuticals
• Melinta  Therapeutics
• Eli  Lilly  and  Company
• Shionogi,  Inc.

• AstraZeneca  plc
12345...Last